Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DXCM NYSE:HIMS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDXCMDexCom$65.12-4.3%$74.42$57.52▼$93.25$26.70B1.476.63 million shs3.50 million shsHIMSHims & Hers Health$53.98-7.3%$50.86$17.36▼$72.98$13.17B2.2528.65 million shs31.66 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDXCMDexCom-4.35%-2.88%-14.32%-21.89%-6.46%HIMSHims & Hers Health-7.15%+2.60%+12.72%+12.67%+188.28%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDXCMDexCom$65.12-4.3%$74.42$57.52▼$93.25$26.70B1.476.63 million shs3.50 million shsHIMSHims & Hers Health$53.98-7.3%$50.86$17.36▼$72.98$13.17B2.2528.65 million shs31.66 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDXCMDexCom-4.35%-2.88%-14.32%-21.89%-6.46%HIMSHims & Hers Health-7.15%+2.60%+12.72%+12.67%+188.28%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDXCMDexCom 2.87Moderate Buy$97.4249.60% UpsideHIMSHims & Hers Health 1.93Reduce$38.92-27.91% DownsideCurrent Analyst Ratings BreakdownLatest DXCM and HIMS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025DXCMDexComWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C-)10/7/2025DXCMDexComCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$105.00 ➝ $85.0010/1/2025DXCMDexComThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$104.00 ➝ $89.009/29/2025DXCMDexComCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$106.009/27/2025DXCMDexComWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C-)9/27/2025HIMSHims & Hers HealthWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)9/26/2025DXCMDexComRobert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$112.00 ➝ $90.009/12/2025HIMSHims & Hers HealthCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$68.009/8/2025DXCMDexComOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Market Perform8/21/2025DXCMDexComArgusSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$100.008/19/2025HIMSHims & Hers HealthZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 10/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDXCMDexCom$4.03B6.33$2.15 per share30.29$5.38 per share12.10HIMSHims & Hers Health$1.48B8.26$0.33 per share165.41$2.16 per share24.99Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDXCMDexCom$576.20M$1.4445.2226.471.4313.29%30.41%10.08%10/30/2025 (Confirmed)HIMSHims & Hers Health$126.04M$0.8067.48103.813.939.63%26.26%13.06%11/3/2025 (Estimated)Latest DXCM and HIMS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/3/2025Q3 2025HIMSHims & Hers Health$0.09N/AN/AN/A$578.99 millionN/A10/30/2025Q3 2025DXCMDexCom$0.57N/AN/AN/A$1.18 billionN/A8/4/2025Q2 2025HIMSHims & Hers Health$0.18$0.17-$0.01$0.17$550.06 million$544.83 million7/30/2025Q2 2025DXCMDexCom$0.45$0.48+$0.03$0.45$1.13 billion$1.16 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDXCMDexComN/AN/AN/AN/AN/AHIMSHims & Hers HealthN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDXCMDexCom0.481.521.35HIMSHims & Hers Health1.724.984.46Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDXCMDexCom97.75%HIMSHims & Hers Health63.52%Insider OwnershipCompanyInsider OwnershipDXCMDexCom0.32%HIMSHims & Hers Health13.71%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDXCMDexCom10,300392.15 million390.90 millionOptionableHIMSHims & Hers Health1,637226.02 million195.03 millionOptionableDXCM and HIMS HeadlinesRecent News About These CompaniesTotal Wealth Planning & Management Inc. Makes New $593,000 Investment in Hims & Hers Health, Inc. $HIMSOctober 11 at 6:21 AM | marketbeat.comSLT Holdings LLC Purchases Shares of 8,125 Hims & Hers Health, Inc. $HIMSOctober 11 at 5:55 AM | marketbeat.comHims & Hers Health, Inc. (HIMS) Dips More Than Broader Market: What You Should KnowOctober 10 at 9:22 PM | msn.comWhy Hims & Hers Health (HIMS) Stock Is NosedivingOctober 10 at 4:21 PM | msn.comTaking Advantage Of Hims & Hers Stock VolatilityOctober 10 at 3:11 PM | investors.comHow Hims & Hers founder Joe Spector turned 10 failures into $1B ideaOctober 9 at 3:06 PM | youtube.comYHims & Hers Expands Personalized Care Access Via Telehealth PlatformOctober 9 at 2:56 PM | zacks.comCustomers Say Care Through Hims & Hers Matches, or Beats, the Doctor’s OfficeOctober 9 at 1:19 PM | finance.yahoo.comAbel Hall LLC Purchases Shares of 4,993 Hims & Hers Health, Inc. $HIMSOctober 9 at 4:28 AM | marketbeat.comRobeco Institutional Asset Management B.V. Trims Position in Hims & Hers Health, Inc. $HIMSOctober 9 at 3:23 AM | marketbeat.comIs Hims & Hers Health Still Attractive After FDA Scrutiny Over Super Bowl Ad?October 9 at 3:14 AM | finance.yahoo.comHims & Hers (HIMS) Jumps on Leadership Changes, Global InitiativesOctober 8 at 5:13 PM | msn.comHims Stock, Up 138%: IBD Stock Of The Day Makes Another Breakout RunOctober 8 at 5:13 PM | msn.comHims & Hers Looks To Close $10 ARPU Gap With Product Expansion And PartnershipsOctober 8 at 8:15 AM | seekingalpha.comJim Cramer Says Hims & Hers is a “Very Hard Stock to Own”October 8 at 6:27 AM | msn.comWill Hims’ (HIMS) Leadership Shift Reveal New Strengths in Operational Execution?October 8 at 6:27 AM | finance.yahoo.comHims & Hers Health (NYSE:HIMS) CFO Sells $669,263.40 in StockOctober 8 at 5:02 AM | insidertrades.comInsider Selling: Hims & Hers Health (NYSE:HIMS) CFO Sells 11,595 Shares of StockOctober 7, 2025 | marketbeat.comHims & Hers Health (NYSE:HIMS) Trading 5.8% Higher - Here's What HappenedOctober 7, 2025 | marketbeat.comHims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should KnowOctober 7, 2025 | zacks.com111 Capital Sells 6,970 Shares of Hims & Hers Health, Inc. $HIMSOctober 5, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025The Fed Cut Rates: What Now for the S&P 500 and Equity Markets?By Thomas Hughes | September 18, 2025Why Datavault May Be the Penny AI Stock Investors Have Waited ForBy Nathan Reiff | September 22, 2025Hims & Hers Stock Pushes to Highs on Healthcare Rate Cut FrenzyBy Gabriel Osorio-Mazilli | September 21, 2025Best Bang For Your Buck? 2 Bargain Stocks with 30%+ UpsideBy Nathan Reiff | September 14, 2025DXCM and HIMS Company DescriptionsDexCom NASDAQ:DXCM$65.12 -2.96 (-4.35%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$65.06 -0.06 (-0.09%) As of 10/10/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.Hims & Hers Health NYSE:HIMS$53.98 -4.27 (-7.33%) Closing price 10/10/2025 03:59 PM EasternExtended Trading$53.24 -0.74 (-1.37%) As of 10/10/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Gets Second $420 Target as CPO Win Boosts Outlook Why Amazon’s Prime Day May Be the Catalyst for a Year-End Rally PepsiCo’s Deep Discount Will Soon Evaporate: Buy It While You Can Bargain Alert: DraftKings Is the Most Oversold It’s Ever Been Constellation Brands: Buffett’s $2.2B Bet May Have Hit Bottom How Gamers Are Powering Microsoft’s Next Wave of Growth AI Meets Nuclear: Palantir’s Role in Energy Expansion Buy the Dip? Zillow’s Profit Comeback Meets Market Pressure Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
